A recent study indicates that approximately 3.6 million Medicare beneficiaries could be eligible for coverage of Novo Nordisk's Wegovy, an obesity treatment also approved for heart disease risk reduction. This follows Medicare's decision to include Wegovy in its coverage, potentially benefiting a significant portion of patients with obesity or overweight conditions. The FDA approved Wegovy for heart disease treatments in March.
About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows https://t.co/wOJtgR4nfl https://t.co/tjUdiKN9Kz
The market for the weight loss drug Wegovy is expanding after a new study found around 3.6 million people with heart disease on Medicare will have access. The FDA approved the drug for heart treatments in March. @business https://t.co/iokAoVcmfz
1 big number: 3.6 million Medicare enrollees could be eligible for Wegovy https://t.co/1csquRttex #axiosvitals
1 in 4 Medicare Beneficiaries With Obesity or Overweight Could Be Eligible for Coverage of Wegovy https://t.co/M0QwbaWjEx
Medicare’s recent decision to cover Novo Nordisk’s blockbuster obesity shot Wegovy for heart disease will possibly subsidize the drug for some 3.6 million people, according to a new study. https://t.co/yfKPOH8kbL
More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says https://t.co/VMUWm6iSqu